Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Alexander M.M. Eggermont(University Medical Center Utrecht), Ulrich Keilholz(German Cancer Research Center), Dirk Schadendorf(National Center for Tumor Diseases), Cornelis J.A. Punt(Utrecht University), Gaetan de Schaetzen(Institut Jules Bordet), Stefan Suciu(St James's University Hospital), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), François Salès(Institut Jules Bordet), Reinhard Dummer(University Hospital of Zurich), Caroline Robert(Institut Gustave Roussy), Poulam M. Patel(Institut Jules Bordet), Jeremy Marsden(NIHR Surgical Reconstruction and Microbiology Research Centre), Alan Spatz(Jewish General Hospital), Wim H.J. Kruit(Erasmus MC), Alessandro Testori(European Organisation for Research and Treatment of Cancer)
Cited by 281
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.8k